Pubblicazioni

Autori:

Belluomini, Lorenzo; Avancini, Alice; Sposito, Marco; Milella, Michele; Rossi, Antonio; Pilotto, Sara

Titolo:

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Anno:

2023

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

EXPERT OPINION ON BIOLOGICAL THERAPY

ISSN Rivista:

1471-2598

N° Volume:

23

Numero o Fascicolo:

11

Editore:

Ashley Publications Limited:Unitec House, Third Floor, 2 Albert Place, Finchley Central, London N3 1QB United Kingdom:011 44 208 3433883, EMAIL: jdrake@ashley-pub.com, INTERNET: http://www.ashley-pub.com, Fax: 011 44 208 3432313

Intervallo pagine:

1077-1087

Parole chiave:

ADCs; TROP-2; datopotamab deruxtecan; non-small cell lung cancer; sacituzumab govitecan; small cell lung cancer

Breve descrizione dei contenuti:

Introduction: The advent of antibody-drug conjugates (ADCs) represents a renewed strategy in the era of precision oncology. Several epithelial tumors harbor overexpression of the trophoblast cell-surface antigen 2 (TROP-2), which represents a predictor of poor prognosis and a promising target for anticancer therapy. Areas covered: In this review, we aim to collect the available preclinical and clinical data regarding anti-TROP-2 ADCs in lung cancer obtained through extensive literature research and screening of the available abstract/posters presented at recent meetings. Expert opinion: Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cell lung cancer subtypes, pending the results of several ongoing trials. The proper combination and placement of this agent throughout the lung cancer treatment pathway, the identification of potentially predictive biomarkers of benefit, as well as the optimal management and impact of peculiar toxicity (i.e. interstitial lung disease) are the next questions to be answered.

Pagina Web:

https://doi.org/10.1080/14712598.2023.2198087

Id prodotto:

133378

Handle IRIS:

11562/1092346

ultima modifica:

29 dicembre 2023

Citazione bibliografica:

Belluomini, Lorenzo; Avancini, Alice; Sposito, Marco; Milella, Michele; Rossi, Antonio; Pilotto, Sara, Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer «EXPERT OPINION ON BIOLOGICAL THERAPY» , vol. 23 , n. 11 , 2023 , pp. 1077-1087

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo